Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C14H10Cl2NO2.Na.H2O |
| Molecular Weight | 336.146 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.[Na+].CC1=C(Cl)C(NC2=CC=CC=C2C([O-])=O)=C(Cl)C=C1
InChI
InChIKey=QHJLLDJTVQAFAN-UHFFFAOYSA-M
InChI=1S/C14H11Cl2NO2.Na.H2O/c1-8-6-7-10(15)13(12(8)16)17-11-5-3-2-4-9(11)14(18)19;;/h2-7,17H,1H3,(H,18,19);;1H2/q;+1;/p-1
| Molecular Formula | Na |
| Molecular Weight | 22.98976928 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C14H11Cl2NO2 |
| Molecular Weight | 296.149 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | HO |
| Molecular Weight | 17.0073 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Meclofenamic acid, used as Meclofenamate sodium, is a non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. Meclofenamate sodium capsules are indicated for the relief of mild to moderate pain, for the treatment of primary dysmenorrhea and for the treatment of idiopathic heavy menstrual blood loss; for relief of signs and symptoms of juvenile arthritis; so as for relief of the signs and symptoms of rheumatoid arthritis; For relief of the signs and symptoms of osteoarthritis. The mode of action, like that of other nonsteroidal anti-inflammatory agents, is not known. Therapeutic action does not result from pituitary-adrenal stimulation. In animal studies, meclofenamate sodium was found to inhibit prostaglandin synthesis and to compete for binding at the prostaglandin receptor site. In vitro, meclofenamate sodium was found to be an inhibitor of human leukocyte 5-lipoxygenase activity. These properties may be responsible for the anti-inflammatory action of meclofenamate sodium. There is no evidence that meclofenamate sodium alters the course of the underlying disease.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2094253 |
|||
Target ID: CHEMBL215 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | MECLOFENAMATE SODIUM Approved UseMeclofenamate sodium capsules are indicated: For reduction of fever in adults; For relief of mild to moderate pain in adults; For relief of signs and symptoms of juvenile arthritis; For relief of the signs and symptoms of rheumatoid arthritis; For relief of the signs and symptoms of osteoarthritis; For treatment of primary dysmenorrhea; For acute or long-term use in the relief of signs and symptoms of the following: Ankylosing spondylitis; Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis); Acute gouty arthritis. Meclofenamate sodium capsules are also indicated for the treatment of idiopathic heavy menstrual blood loss. As with all nonsteroidal anti-inflammatory drugs, selection of meclofenamate sodium capsules require a careful assessment of the benefit/risk ratio. Veclofenamate sodium capsules are not recommended in children because adequate studies to demonstrate safety and efficacy have not been carried out. Launch Date1986 |
|||
| Palliative | MECLOFENAMATE SODIUM Approved UseMeclofenamate sodium capsules are indicated: For reduction of fever in adults; For relief of mild to moderate pain in adults; For relief of signs and symptoms of juvenile arthritis; For relief of the signs and symptoms of rheumatoid arthritis; For relief of the signs and symptoms of osteoarthritis; For treatment of primary dysmenorrhea; For acute or long-term use in the relief of signs and symptoms of the following: Ankylosing spondylitis; Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis); Acute gouty arthritis. Meclofenamate sodium capsules are also indicated for the treatment of idiopathic heavy menstrual blood loss. As with all nonsteroidal anti-inflammatory drugs, selection of meclofenamate sodium capsules require a careful assessment of the benefit/risk ratio. Veclofenamate sodium capsules are not recommended in children because adequate studies to demonstrate safety and efficacy have not been carried out. Launch Date1986 |
|||
| Palliative | MECLOFENAMATE SODIUM Approved UseMeclofenamate sodium capsules are indicated: For reduction of fever in adults; For relief of mild to moderate pain in adults; For relief of signs and symptoms of juvenile arthritis; For relief of the signs and symptoms of rheumatoid arthritis; For relief of the signs and symptoms of osteoarthritis; For treatment of primary dysmenorrhea; For acute or long-term use in the relief of signs and symptoms of the following: Ankylosing spondylitis; Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis); Acute gouty arthritis. Meclofenamate sodium capsules are also indicated for the treatment of idiopathic heavy menstrual blood loss. As with all nonsteroidal anti-inflammatory drugs, selection of meclofenamate sodium capsules require a careful assessment of the benefit/risk ratio. Veclofenamate sodium capsules are not recommended in children because adequate studies to demonstrate safety and efficacy have not been carried out. Launch Date1986 |
|||
| Palliative | MECLOFENAMATE SODIUM Approved UseMeclofenamate sodium capsules are indicated: For reduction of fever in adults; For relief of mild to moderate pain in adults; For relief of signs and symptoms of juvenile arthritis; For relief of the signs and symptoms of rheumatoid arthritis; For relief of the signs and symptoms of osteoarthritis; For treatment of primary dysmenorrhea; For acute or long-term use in the relief of signs and symptoms of the following: Ankylosing spondylitis; Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis); Acute gouty arthritis. Meclofenamate sodium capsules are also indicated for the treatment of idiopathic heavy menstrual blood loss. As with all nonsteroidal anti-inflammatory drugs, selection of meclofenamate sodium capsules require a careful assessment of the benefit/risk ratio. Veclofenamate sodium capsules are not recommended in children because adequate studies to demonstrate safety and efficacy have not been carried out. Launch Date1986 |
|||
| Palliative | MECLOFENAMATE SODIUM Approved UseMeclofenamate sodium capsules are indicated: For reduction of fever in adults; For relief of mild to moderate pain in adults; For relief of signs and symptoms of juvenile arthritis; For relief of the signs and symptoms of rheumatoid arthritis; For relief of the signs and symptoms of osteoarthritis; For treatment of primary dysmenorrhea; For acute or long-term use in the relief of signs and symptoms of the following: Ankylosing spondylitis; Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis); Acute gouty arthritis. Meclofenamate sodium capsules are also indicated for the treatment of idiopathic heavy menstrual blood loss. As with all nonsteroidal anti-inflammatory drugs, selection of meclofenamate sodium capsules require a careful assessment of the benefit/risk ratio. Veclofenamate sodium capsules are not recommended in children because adequate studies to demonstrate safety and efficacy have not been carried out. Launch Date1986 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
15.1 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2322633/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
MECLOFENAMIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
30.2 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2322633/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
MECLOFENAMIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2322633/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
MECLOFENAMIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
| Dose | Population | Adverse events |
|---|---|---|
400 mg 1 times / day multiple, oral Dose: 400 mg, 1 times / day Route: oral Route: multiple Dose: 400 mg, 1 times / day Sources: |
unhealthy |
Other AEs: Diarrhoea... |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Diarrhoea | 400 mg 1 times / day multiple, oral Dose: 400 mg, 1 times / day Route: oral Route: multiple Dose: 400 mg, 1 times / day Sources: |
unhealthy |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Endothelium-dependent relaxation of isolated splanchnic arteries from cirrhotic patients: Role of reactive oxygen species. | 2007-10 |
|
| Differential effects of losartan and candesartan on vasoconstrictor responses in the rat. | 2007-07-07 |
|
| Molecular expression and pharmacological identification of a role for K(v)7 channels in murine vascular reactivity. | 2007-07 |
|
| Simultaneous determination of various pharmaceutical compounds in water by solid-phase extraction-liquid chromatography-tandem mass spectrometry. | 2007-06-22 |
|
| Non-steroidal anti-inflammatory drugs increase insulin release from beta cells by inhibiting ATP-sensitive potassium channels. | 2007-06 |
|
| Spurious urine excretion drug profile in the horse due to bedding contamination and drug recycling: the case of meclofenamic acid. | 2007-04 |
|
| Alpha2-adrenoreceptor mediated sympathoinhibition of heart rate during acute hypoxia is diminished in conscious prostacyclin synthase deficient mice. | 2007-04 |
|
| Role for prostaglandins in the regulation of type 1 11beta-hydroxysteroid dehydrogenase in human granulosa-lutein cells. | 2006-12 |
|
| Allosteric modulation of [3H]EBOB binding to GABAA receptors by diflunisal analogues. | 2006-12 |
|
| Angiotensin-(1-7) potentiates responses to bradykinin but does not change responses to angiotensin I. | 2006-11 |
|
| Inhibition of human phenol and estrogen sulfotransferase by certain non-steroidal anti-inflammatory agents. | 2006-10 |
|
| Meclofenamic acid extends donor-recipient asynchrony in equine embryo transfer. | 2006-09 |
|
| Hemopressin, a hemoglobin fragment, dilates the rat systemic vascular bed through release of nitric oxide. | 2006-09 |
|
| Cyclooxygenase-2 inhibition normalizes arterial blood pressure in CYP1A1-REN2 transgenic rats with inducible ANG II-dependent malignant hypertension. | 2006-09 |
|
| Early aging and anatomic heterogeneity determine cyclooxygenase-mediated vasoconstriction to angiotensin II in mice. | 2006-08 |
|
| Antiepileptic effect of gap-junction blockers in a rat model of refractory focal cortical epilepsy. | 2006-07 |
|
| Use of accelerating solvent extraction for detecting non-steroidal anti-inflammatory drugs in horse feces. | 2006-06 |
|
| Intermedin/adrenomedullin-2 dilates the rat pulmonary vascular bed: dependence on CGRP receptors and nitric oxide release. | 2006-06 |
|
| Starch-based microspheres produced by emulsion crosslinking with a potential media dependent responsive behavior to be used as drug delivery carriers. | 2006-04 |
|
| Second-order calibration of excitation-emission matrix fluorescence spectra for the determination of N-phenylanthranilic acid derivatives. | 2006-03 |
|
| Partial renal ischemia elicits heterogeneous control of renal sympathetic nerve activity to ischemic and nonischemic regions of the kidney. | 2006-02 |
|
| Vasoconstrictor prostanoids may be involved in reduced coronary reactive hyperemia after ischemia-reperfusion in anesthetized goats. | 2006-01-20 |
|
| QSAR analysis of meclofenamic acid analogues as selective COX-2 inhibitors. | 2006-01-15 |
|
| Determination of fourteen non-steroidal anti-inflammatory drugs in animal serum and plasma by liquid chromatography/mass spectrometry. | 2006 |
|
| Analysis of responses to kava kava in the feline pulmonary vascular bed. | 2006 |
|
| Enhanced response of pig coronary arteries to endothelin-1 after ischemia-reperfusion. Role of endothelin receptors, nitric oxide and prostanoids. | 2005-11-07 |
|
| Nonsynaptic GABA signaling in postnatal subventricular zone controls proliferation of GFAP-expressing progenitors. | 2005-09 |
|
| Increased myogenic tone in 7-month-old adult male but not female offspring from rat dams exposed to hypoxia during pregnancy. | 2005-08 |
|
| Coronary effects of endothelin-1 and vasopressin during acute hypotension in anesthetized goats. | 2005-06-10 |
|
| Mechanisms of the protective effects of urocortin on coronary endothelial function during ischemia-reperfusion in rat isolated hearts. | 2005-06 |
|
| Meclofenamic acid and diclofenac, novel templates of KCNQ2/Q3 potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties. | 2005-04 |
|
| Biomarkers of oxidative stress study III. Effects of the nonsteroidal anti-inflammatory agents indomethacin and meclofenamic acid on measurements of oxidative products of lipids in CCl4 poisoning. | 2005-03-15 |
|
| Tracking acidic pharmaceuticals, caffeine, and triclosan through the wastewater treatment process. | 2005-01 |
|
| Embryo transfer in the dromedary camel (Camelus dromedarius) using asynchronous, meclofenamic acid-treated recipients. | 2005 |
|
| Effects of lornoxicam on the physiology of severe sepsis. | 2004-12 |
|
| Responses to bradykinin are mediated by NO-independent mechanisms in the rat hindlimb vascular bed. | 2004-12 |
|
| Compounds exhibiting selective efficacy for different beta subunits of human recombinant gamma-aminobutyric acid A receptors. | 2004-11 |
|
| Analysis of gamma-aminobutyric acid-mediated responses in the pulmonary vascular bed of the cat. | 2004-09 |
|
| Roles for prostaglandins in the steroidogenic response of human granulosa cells to high-density lipoproteins. | 2004-07-30 |
|
| Vasopressin effects on the coronary circulation after a short ischemia in anesthetized goats: role of nitric oxide and prostanoids. | 2004-07-14 |
|
| Myogenic reactivity is enhanced in rat radial uterine arteries in a model of maternal undernutrition. | 2004-07 |
|
| Race-specific differences in endothelial function: predisposition of African Americans to vascular diseases. | 2004-06-01 |
|
| Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs. | 2004-06 |
|
| Coronary action of endothelin-1 and vasopressin during acute hypertension in anesthetized goats. Role of nitric oxide and prostanoids. | 2004-05-27 |
|
| Topical NSAIDs for acute pain: a meta-analysis. | 2004-05-17 |
|
| Role of potassium channels in the nitric oxide-independent vasodilator response to acetylcholine. | 2004-03 |
|
| Effects of chronic PGHS-2 inhibition on PGHS-dependent vasoconstriction in the aged female rat. | 2004-02-01 |
|
| Analysis of responses to St. John's Wort in the feline pulmonary vascular bed. | 2004 |
|
| Comparison of the in vivo coronary action of endothelin-1 and vasopressin role of nitric oxide and prostanoids. | 2003-12 |
|
| Analysis of responses to valerian root extract in the feline pulmonary vascular bed. | 2003-12 |
Sample Use Guides
For Mild to Moderate Pain:
The recommended dose is 50 mg every 4 to 6 hours. Doses of 100 mg may be needed in some patients for optimal pain relief
For excessive menstrual blood loss and primary dysmenorrheal:
The recommended dose of meclofenamate sodium is 100 mg 3 times a day, for up to 6 days, starting at the onset of menstrual flow.
For rheumatoid arthritis and osteoarthritis (including acute exacerbations of chronic disease):
The dosage is 200 mg to 400 mg per day, administered in three or four equal doses.
Route of Administration:
Oral
The meclofenamic acid was tested in murine models immunodeficient and immunocompetent) of Uterine cervical cancer (UCC), which manifested a significant reduction in tumor growth and increased mouse survival. It was demonstrated that meclofenamic acid was the most cytotoxic, with a significant antitumor effect in murine models. Cytotoxicity assay performed with two repetitions. In a first selection assay meclofenamic acid was used in concentrations of 100 µM. In a subsequent assay, the mefenamic acid was used in concentrations of 0, 7.5, 15, 30, 60, 120 and 240 µM.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:57:53 GMT 2025
by
admin
on
Mon Mar 31 17:57:53 GMT 2025
|
| Record UNII |
94NJ818U2W
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C257
Created by
admin on Mon Mar 31 17:57:53 GMT 2025 , Edited by admin on Mon Mar 31 17:57:53 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
23663959
Created by
admin on Mon Mar 31 17:57:53 GMT 2025 , Edited by admin on Mon Mar 31 17:57:53 GMT 2025
|
PRIMARY | |||
|
76232
Created by
admin on Mon Mar 31 17:57:53 GMT 2025 , Edited by admin on Mon Mar 31 17:57:53 GMT 2025
|
PRIMARY | |||
|
CHEMBL509
Created by
admin on Mon Mar 31 17:57:53 GMT 2025 , Edited by admin on Mon Mar 31 17:57:53 GMT 2025
|
PRIMARY | |||
|
67254-91-5
Created by
admin on Mon Mar 31 17:57:53 GMT 2025 , Edited by admin on Mon Mar 31 17:57:53 GMT 2025
|
PRIMARY | |||
|
1377803
Created by
admin on Mon Mar 31 17:57:53 GMT 2025 , Edited by admin on Mon Mar 31 17:57:53 GMT 2025
|
PRIMARY | |||
|
SUB03106MIG
Created by
admin on Mon Mar 31 17:57:53 GMT 2025 , Edited by admin on Mon Mar 31 17:57:53 GMT 2025
|
PRIMARY | |||
|
94NJ818U2W
Created by
admin on Mon Mar 31 17:57:53 GMT 2025 , Edited by admin on Mon Mar 31 17:57:53 GMT 2025
|
PRIMARY | |||
|
DBSALT001241
Created by
admin on Mon Mar 31 17:57:53 GMT 2025 , Edited by admin on Mon Mar 31 17:57:53 GMT 2025
|
PRIMARY | |||
|
300000040293
Created by
admin on Mon Mar 31 17:57:53 GMT 2025 , Edited by admin on Mon Mar 31 17:57:53 GMT 2025
|
PRIMARY | |||
|
C47597
Created by
admin on Mon Mar 31 17:57:53 GMT 2025 , Edited by admin on Mon Mar 31 17:57:53 GMT 2025
|
PRIMARY | |||
|
6677
Created by
admin on Mon Mar 31 17:57:53 GMT 2025 , Edited by admin on Mon Mar 31 17:57:53 GMT 2025
|
PRIMARY | RxNorm | ||
|
94NJ818U2W
Created by
admin on Mon Mar 31 17:57:53 GMT 2025 , Edited by admin on Mon Mar 31 17:57:53 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ANHYDROUS->SOLVATE | |||
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
IMPURITY -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |